Imperial acquires D. Anderson & Company; expands clinical trial services
The deal represents the first corporate acquisition of a patient recruitment organisation by Imperial which, according to the company, helps “increase Imperial’s global presence within the clinical trial industry.”
Matthew Bissell, president and CEO of Imperial said the deal marked an important day for the company and its clients.
“Independently, each company is a global leader respected for quality, integrity and ingenuity,” he said. “Together, we are a global force, with the capacity to serve clinical trial sponsors regardless of need, size, location or disease sector.”
Imperial is perhaps best known for its iWorx platform: a flexible suite of clinical trials services the company claims can be tailored to suit a client’s needs.
Intellectual bandwidth
Dallas, US-based D. Anderson & Company specialises in developing patient recruitment and retention campaigns for clinical trials across five continents and 40 disease indications.
Diana Anderson, president and CEO of D. Anderson & Company, welcomed what she described as a new era for the company.
“Clients will benefit from the bandwidth of our intellectual resources, world reach and ability to provide unparalleled support services for international clinical trials,” she said.
According to D. Anderson, the company has experienced 3 years of exponential growth prior to their acquisition by Imperial, with international business now accounting for 63 per cent of overall sales.
Optimally positioned
Vice president and COO of Imperial, Steve Swanson, echoed the earlier sentiments expressed by Bissell, claiming the combined resources of both companies made them an attractive choice for prospective clients.
“United we are optimally positioned to exceed client expectations in the high stakes field of clinical research,” he said.
“The blending of talent and resources will help us meet growing demands for comprehensive services, competitive pricing and global presence.”
